$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa

$zvsa Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041185 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.519M	$2.229M	$3.500M
YoY Change	-56.6%	110.26%	207.02%
% of Gross Profit
Research & Development	$257.1K	$673.9K	$399.9K
YoY Change	-35.71%	-71.08%	-36.52%
% of Gross Profit
Depreciation & Amortization	$2.600K	-$2.200K	$532.00
YoY Change	388.72%
% of Gross Profit
Operating Expenses	$1.776M	$2.903M	$820.1K
YoY Change	116.59%	194.51%	251.66%
Operating Profit		-$2.903M	-$820.1K
YoY Change		194.51%
Interest Expense	-$100.00	-$210.00	-$240.0K
YoY Change	-99.96%	-100.06%	4319.89%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$13.93M	-$2.903M	-$5.420M
YoY Change	157.1%	359.65%	1599.06%
Income Tax	-$596.1K	-$485.00	-$745.1K
% Of Pretax Income
Net Earnings	-$13.34M	-$2.902M	-$75.02K
YoY Change	17680.4%	327.4%	-76.48%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.09	-$0.01
Diluted Earnings Per Share	-$5.96	-$0.09	-$0.51
COMMON SHARES
Basic Shares Outstanding	43.52M shares	30.89M shares	9.016M shares
Diluted Shares Outstanding		30.98M shares	257.6K shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.138M	$1.579M	$5.900M
YoY Change	-46.82%	639.24%	535.78%
Cash & Equivalents	$3.138M	$1.579M	$5.902M
Short-Term Investments
Other Short-Term Assets	$215.5K	$426.5K	$400.0K
YoY Change	-46.14%	89.56%	58.73%
Inventory
Prepaid Expenses			$225.3K
Receivables
Other Receivables
Total Short-Term Assets	$3.353M	$2.005M	$6.363M
YoY Change	-47.3%	357.23%	439.11%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.933K	$9.533K	$17.33K
YoY Change	-60.0%
Goodwill			$11.90M
YoY Change
Intangibles		$30.81M	$100.1M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$18.65M	$0.00	$100.1M
YoY Change	-81.37%	-100.0%	31.76%
Total Long-Term Assets	$18.76M	$30.85M	$112.1M
YoY Change	-83.27%	-60.93%	47.63%
TOTAL ASSETS
Total Short-Term Assets	$3.353M	$2.005M	$6.363M
Total Long-Term Assets	$18.76M	$30.85M	$112.1M
Total Assets	$22.11M	$32.85M	$118.5M
YoY Change	-81.34%	-58.62%	53.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.432M	$8.898M	$6.026M
YoY Change	39.93%	36.89%
Accrued Expenses	$1.755M	$2.775M	$2.054M
YoY Change	-14.56%	70.78%	925.51%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.19M	$11.71M	$8.188M
YoY Change	24.51%	620.39%	2857.7%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.19M	$11.71M	$8.188M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$11.04M	$13.15M	$18.51M
YoY Change	-40.36%	162.96%	406.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$103.2M	-$89.90M	-$4.921M
YoY Change	1997.45%	2061.48%	117.87%
Common Stock	$405.00	$4.353K	$902.00
YoY Change	-55.1%	13503.13%	2718.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$7.168K	$7.168K
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.07M	$19.70M	$99.66M
YoY Change
Total Liabilities & Shareholders Equity	$22.11M	$32.85M	$118.5M
YoY Change	-81.34%	-58.62%	53.62%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$13.34M	-$2.902M	-$75.02K
YoY Change	17680.4%	327.4%	-76.48%
Depreciation, Depletion And Amortization	$2.600K	-$2.200K	$532.00
YoY Change	388.72%
Cash From Operating Activities	-$2.787M	-$933.5K	-$3.394M
YoY Change	-17.87%	638.04%	493.34%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.346M	2.290M
YoY Change
NET CHANGE
Cash From Operating Activities	-2.787M	-933.5K	-$3.394M
Cash From Investing Activities
Cash From Financing Activities	4.346M	2.290M
Net Change In Cash	1.559M	1.357M	-$3.394M
YoY Change	-145.93%	-1172.52%	-719.32%
FREE CASH FLOW
Cash From Operating Activities	-$2.787M	-$933.5K	-$3.394M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001859007
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q3	us-gaap	Deposit Assets DepositAssets		usd
CY2023Q3	us-gaap	Goodwill Goodwill		usd
CY2023Q3	us-gaap	Security Deposit SecurityDeposit		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2023Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2023Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	ZVSA	Conversion Of Convertible Notes Payable And Accrued Interest Into Preferred Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoPreferredStock		usd
	ZVSA	Recognition Of Rou Asset And Lease Liability RecognitionOfRouAssetAndLeaseLiability		usd
CY2023Q3	ZVSA	Note Payable NotePayable		usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent		usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q3	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Warrants Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOptionsOutstandingIntrinsicValue		usd
CY2023Q3	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOptionsExercisableIntrinsicValue1		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41184
	dei	Entity Registrant Name EntityRegistrantName	ZYVERSA THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2685744
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2200 N. Commerce Parkway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 208
	dei	Entity Address City Or Town EntityAddressCityOrTown	Weston
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33326
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33326
	dei	City Area Code CityAreaCode	(754)
	dei	Local Phone Number LocalPhoneNumber	231-1688
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	ZVSA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43519719	shares
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023Q3	us-gaap	Cash Cash	1578721	usd
CY2022Q4	us-gaap	Cash Cash	5902199	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	426519	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	225347	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	235000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	2005240	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6362546	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9533	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17333	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	30806158	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	100086329	usd
CY2022Q4	us-gaap	Goodwill Goodwill	11895033	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	46659	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31078	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	98371	usd
CY2023Q3	us-gaap	Assets Assets	32852009	usd
CY2022Q4	us-gaap	Assets Assets	118506271	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	8897534	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6025645	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2775485	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2053559	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	34349	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108756	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11707368	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8187960	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1440982	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10323983	usd
CY2023Q3	us-gaap	Liabilities Liabilities	13148350	usd
CY2022Q4	us-gaap	Liabilities Liabilities	18511943	usd
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	65783	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	331331	usd
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	110000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43517560	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9016139	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43515401	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9016139	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	4353	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	902	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	109587097	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	104583271	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-89880624	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4921178	usd
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	2159	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	7168	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	19703659	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	99662997	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32852009	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118506271	usd
CY2023Q3	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	673943	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2950462	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2228735	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9694097	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	69280171	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11895033	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2902678	usd
	us-gaap	Operating Expenses OperatingExpenses	93819763	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2902678	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-93819763	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-210	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	555	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2902888	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-93819208	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-485	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8859762	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2902403	usd
	us-gaap	Net Income Loss NetIncomeLoss	-84959446	usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	32373	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	7948209	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2934776	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-92907655	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.79
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30978540	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30978540	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19403027	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19403027	shares
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	99662997	usd
CY2023Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	331331	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	395200	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-34674	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	287461	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-3543950	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	97098365	usd
CY2023Q2	ZVSA	Registered Offering Of Common Stock Value RegisteredOfferingOfCommonStockValue	9831019	usd
CY2023Q2	ZVSA	Preferred Stock Redeemed Or Called During Period Value PreferredStockRedeemedOrCalledDuringPeriodValue	-10080001	usd
CY2023Q2	ZVSA	Shares Issued As Consideration For Extension Of Lockup Period Value SharesIssuedAsConsiderationForExtensionOfLockupPeriodValue	1156778	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	210000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	365742	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-7168	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-78513093	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	20061642	usd
CY2023Q3	ZVSA	Registered Offering Of Common Stock Value RegisteredOfferingOfCommonStockValue	1575938	usd
CY2023Q3	ZVSA	Adjustments To Additional Paid In Capital Warrant Modification AdjustmentsToAdditionalPaidInCapitalWarrantModification	181891	usd
CY2023Q3	ZVSA	Preferred Stock Redeemed Or Called During Period Value PreferredStockRedeemedOrCalledDuringPeriodValue	-215048	usd
CY2023Q3	ZVSA	Exercise Of Prefunded Warrants ExerciseOfPrefundedWarrants	947	usd
CY2023Q3	ZVSA	Stock Issued During Period Value Warrant Inducement Offer Exercise Proceeds StockIssuedDuringPeriodValueWarrantInducementOfferExerciseProceeds	757647	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	243045	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2902403	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	19703659	usd
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Net Income Loss NetIncomeLoss	-84959446	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	69280171	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	11895033	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	896248	usd
	ZVSA	Issuance Of Common Stock Pursuant To Vendor IssuanceOfCommonStockPursuantToVendor	605200	usd
	ZVSA	Shares Issued As Consideration For Extension Of Lockup Period SharesIssuedAsConsiderationForExtensionOfLockupPeriod	1156778	usd
	us-gaap	Depreciation Depreciation	7800	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	67293	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-8883001	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	201172	usd
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	46659	usd
	ZVSA	Increase Decrease In Vendor Deposits IncreaseDecreaseInVendorDeposits	235000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2871889	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-74407	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1122488	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5933467	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13114555	usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1763584	usd
	ZVSA	Redemption Of Series Preferred Stock RedemptionOfSeriesPreferredStock	10695610	usd
	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	7168	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	947	usd
	ZVSA	Warrant Inducement Offer Exercise Proceeds WarrantInducementOfferExerciseProceeds	966349	usd
	ZVSA	Registration And Issuance Costs Associated With Preferred Stock Issuance RegistrationAndIssuanceCostsAssociatedWithPreferredStockIssuance	5500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1609989	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4323478	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5902199	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1578721	usd
	ZVSA	Reclassification Of Formerly Redeemable Common Stock ReclassificationOfFormerlyRedeemableCommonStock	331331	usd
	ZVSA	Accounts Payable For Deferred Offering Costs AccountsPayableForDeferredOfferingCosts	44892	usd
	ZVSA	Warant Modification Incremental Value WarantModificationIncrementalValue	181891	usd
	ZVSA	Warrant Inducement Offer Incremental Value WarrantInducementOfferIncrementalValue	134591	usd
CY2023Q3	us-gaap	Cash Cash	1600000	usd
CY2023Q3	ZVSA	Working Capital Deficit WorkingCapitalDeficit	9700000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-85000000.0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5900000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-89900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zz5wT8d8SDEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zXZbED36IvPk">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	40682895	shares
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.94
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	699324	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets	1093223	usd
CY2022Q4	ZVSA	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inprocess Research And Development BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInprocessResearchAndDevelopment	100086329	usd
CY2022Q4	us-gaap	Goodwill Goodwill	11895033	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	64523	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	113139108	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	10818204	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	11069033	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	21887237	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	91251871	usd
CY2023Q3	ZVSA	Milestone Payment Liability MilestonePaymentLiability	500000	usd
CY2022Q4	ZVSA	Milestone Payment Liability MilestonePaymentLiability	1500000	usd
CY2022Q4	ZVSA	Note Payable NotePayable	-351579	usd
CY2023Q3	ZVSA	Note Net NoteNet	500000	usd
CY2022Q4	ZVSA	Note Net NoteNet	1148421	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	894416	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	584226	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	31969	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	214229	usd
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	129922	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	106683	usd
CY2023Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1212359	usd
CY2023Q3	us-gaap	Other Liabilities OtherLiabilities	6819	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2775485	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2053559	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0944	pure
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0944	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	ten
CY2023Q1	ZVSA	Milestone Payment Description MilestonePaymentDescription	The Company entered into a License Agreement with L&F Research LLC (“L&F Research”) effective December 15, 2015, as amended (the “L&F License Agreement”) pursuant to which L&F granted us an exclusive royalty-bearing, worldwide, sublicensable license under the patent and intellectual property rights and know-how specific to and for the development and commercialization of VAR 200, for the treatment, inhibition or prevention of kidney disease in humans and symptoms thereof, including focal segmental glomerulosclerosis. On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waived L&F’s right to terminate the L&F License Agreement or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”).
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023Q3	ZVSA	Operating Lease Asset Amortization OperatingLeaseAssetAmortization	38885	usd
	ZVSA	Operating Lease Asset Amortization OperatingLeaseAssetAmortization	116083	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	74405	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y4M2D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	34822	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	472	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	34349	usd
CY2023Q2	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	6700000	usd
CY2023Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	84315	usd
CY2023Q2	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	2.00
CY2023Q3	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	243045	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	494022	usd
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	896249	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3131708	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1324176	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y8M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	ten
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	100000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	184426	usd
CY2023Q1	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm1	P3Y
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	2.11
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	ten
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	13000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23770	usd
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	2.26
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	13000	shares
CY2023Q1	us-gaap	Shares Issued SharesIssued	5000	shares
CY2023Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1453107	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	555004	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	499660	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P3Y
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	55344	usd
CY2023Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.44
CY2023Q3	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1993235	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.81
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1566107	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.56
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3559342	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.30
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1968166	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.53
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2023Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	3559342	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P5Y2M12D
CY2023Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1968166	shares
CY2023Q3	ZVSA	Placement Agent Fees PlacementAgentFees	57980	usd
CY2023Q3	us-gaap	Legal Fees LegalFees	16131	usd
CY2023Q3	ZVSA	Warrant Modification Costs WarrantModificationCosts	134591	usd
CY2023Q3	ZVSA	Incremental Fair Value IncrementalFairValue	134591	usd
CY2023Q3	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
CY2022Q3	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Successor
	us-gaap	Financial Designation Predecessor And Successor Fixed List FinancialDesignationPredecessorAndSuccessorFixedList	Predecessor
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	8628706	shares
CY2022Q4	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	10.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	40335199	shares
	ZVSA	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice	0.39
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	16592426	shares
	ZVSA	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercised In Period Weighted Average Exercised Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisedPrice	0.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	97785	shares
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.00
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOld	-863500	shares
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOldInPeriodWeightedAverageExercisePrice	11.50
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNew	4965125	shares
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNewInPeriodWeightedAverageExercisePrice	2.00
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old Two ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOldTwo	-1377996	shares
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old In Period Weighted Average Exercise Price Old Two ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOldInPeriodWeightedAverageExercisePriceOldTwo	1.00
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New Two ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNewTwo	1377996	shares
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New In Period Weighted Average Exercise Price New Two ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNewInPeriodWeightedAverageExercisePriceNewTwo	0.17
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old Three ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOldThree	-7121213	shares
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced Old In Period Weighted Average Exercise Price Old Three ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedOldInPeriodWeightedAverageExercisePriceOldThree	0.17
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New Three ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNewThree	7121213	shares
	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Repriced New In Period Weighted Average Exercise Price New Three ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsRepricedNewInPeriodWeightedAverageExercisePriceNewThree	0.14
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	36375319	shares
CY2023Q3	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	2.87
	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Options Warrants Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWarrantsOutstandingWeightedAverageRemainingContractualTerm2	P4Y7M6D
CY2023Q3	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	29184304	shares
CY2023Q3	ZVSA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	3.52
	ZVSA	Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y4M24D
CY2023Q1	ZVSA	Percentage Of Registration Delay Payments PercentageOfRegistrationDelayPayments	0.015	pure
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.020	pure
CY2023Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	6819	usd
CY2023Q3	ZVSA	Stock Issued During Period Shares Common Stock Reserved For Issuance StockIssuedDuringPeriodSharesCommonStockReservedForIssuance	4000000	shares
CY2023Q3	ZVSA	Stock Issued During Period Shares Common Stock Reserved For Issuance StockIssuedDuringPeriodSharesCommonStockReservedForIssuance	5453107	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-041185-index-headers.html	Edgar Link	pending
0001493152-23-041185-index.html	Edgar Link	pending
0001493152-23-041185.txt	Edgar Link	pending
0001493152-23-041185-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zvsa-20230930.xsd	Edgar Link	pending
zvsa-20230930_cal.xml	Edgar Link	unprocessable
zvsa-20230930_def.xml	Edgar Link	unprocessable
zvsa-20230930_lab.xml	Edgar Link	unprocessable
zvsa-20230930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa

2023 Q4 Form 10-Q Financial Statement

#000149315223041185 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZVSA ZyVersa Therapeutics, Inc. Stock $zvsa

2023 Q4 Form 10-Q Financial Statement

#000149315223041185 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ZVSA
ZyVersa Therapeutics, Inc. Stock $zvsa